Semarion is a University of Cambridge spin-out integrating materials engineering and cell biology to improve drug discovery workflows. Its SemaCyte microcarrier platform converts adherent cells into barcoded, assay-ready microcarriers, enabling higher-throughput and more reproducible cell-based assays.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| $3.8 M | Mar, 2026 | Unknown |
Frequently Asked Questions
Where is Semarion located?
Semarion is located in Cambridge, United Kingdom.
What industries does Semarion operate in?
Semarion operates in the following industries: biotechnology, drug discovery, life sciences, cell assay platform.
When was Semarion founded?
Semarion was founded on 2026-03-31.
How much total funding has Semarion raised?
Semarion has raised a total of $3,800,000.
Who are the investors in Semarion?
The investors in Semarion are: Unspecified Lead Investor, The FSE Group, Cambridge Enterprise Ventures, Oxford Innovation Finance, Found Capital, Cambridge Capital Group, Start Codon.
What is the core technology offered by Semarion?
Semarion has developed the SemaCyte microcarrier platform, which consists of ultra-miniaturized, magnetically steerable, and barcoded wells that allow adherent cells to be handled as if they were in suspension.
How does Semarion help reduce the time required for cell-based assays?
By using SemaCyte microcarriers, researchers can create assay-ready adherent cells that are batch frozen and stored. This allows them to skip the traditional two-to-three-day cell seeding and attachment phase, making cells ready for experiments within one hour of thawing.
What are the benefits of using Semarion for cell multiplexing?
The platform uses optical barcodes embedded in the microcarriers to distinguish between different cell types or models within a single well. This enables higher-order multiplexing, which can reduce screening time by up to six-fold and reagent costs by up to ten-fold.
Can Semarion's technology be integrated with existing laboratory equipment?
Yes, the platform is designed to be fully compatible with standard liquid handling tools, plate readers, and high-content imaging systems, requiring no new specialized equipment for integration into current workflows.
How does Semarion facilitate the miniaturization of assays?
Semarion microcarriers allow for the use of significantly fewer cells per assay, typically five to one hundred times less than traditional methods, while still maintaining high local confluency and cell health.
What types of cell models are compatible with Semarion's SemaCytes?
The technology is validated across a wide range of cell models, including various cancer cell lines, primary patient samples, and iPSC-derived cells, providing flexibility for different areas of life science research and drug discovery.